Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 2;4:834. doi: 10.1038/s42003-021-02352-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Heatmap showed the response of 20 NSCLC lines to 5-day Erlotinib treatment (0, 0.1, 0.3, 1, 3, 10 µM) in individual CellTiter-Glo assay (top) or PRISM assay (bottom). b EGFR gene dependency of 20 NSCLC lines was evaluated by CRISPR competition assay (7 day, solid circles) and PRISM assay (5 day, solid squares). EGFR gene was knocked out by two single guide RNAs (sgEGFR1 and sgEGFR2), respectively. c Correlation analysis of Erlotinib AUC in individual CTG assay vs PRISM assay (20 cell lines, r = 0.9097). d Correlation analysis of Erlotinib AUC in PRISM assay vs AUC reported by Cancer Therapeutics Response Portal (CTRPv2, 18 cell lines, r = 0.7969). e Correlation analysis of EGFR CRISPR competition assay vs PRISM assay (plotted with average of two sgRNAs, 20 cell lines, r = 0.6844). f Correlation analysis of EGFR CRISPR PRISM assay vs DepMap gene effect score (CERES, 15 cell lines, r = 0.5098).